Shengying Gu

455 total citations
17 papers, 361 citations indexed

About

Shengying Gu is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Cancer Research. According to data from OpenAlex, Shengying Gu has authored 17 papers receiving a total of 361 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Cancer Research. Recurrent topics in Shengying Gu's work include Diabetes Treatment and Management (4 papers), Advancements in Transdermal Drug Delivery (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Shengying Gu is often cited by papers focused on Diabetes Treatment and Management (4 papers), Advancements in Transdermal Drug Delivery (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Shengying Gu collaborates with scholars based in China. Shengying Gu's co-authors include Liu Gao-lin, Xin Wu, Jigang Zhang, Guanhua Zhu, Yuzhu Wang, Ying Liu, Xiaoyu Li, Xin Wu, Yuzhu Wang and Dandan Zhang and has published in prestigious journals such as PLoS ONE, European Journal of Pharmaceutics and Biopharmaceutics and Frontiers in Pharmacology.

In The Last Decade

Shengying Gu

17 papers receiving 359 citations

Peers

Shengying Gu
Xiaohua Pei China
Wenbin Xu China
Anhui Gao China
Die Qian China
Junli Zhang China
Puyang Gong China
Rong Lin China
Chengwu Shen China
Xiaohua Pei China
Shengying Gu
Citations per year, relative to Shengying Gu Shengying Gu (= 1×) peers Xiaohua Pei

Countries citing papers authored by Shengying Gu

Since Specialization
Citations

This map shows the geographic impact of Shengying Gu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengying Gu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengying Gu more than expected).

Fields of papers citing papers by Shengying Gu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shengying Gu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengying Gu. The network helps show where Shengying Gu may publish in the future.

Co-authorship network of co-authors of Shengying Gu

This figure shows the co-authorship network connecting the top 25 collaborators of Shengying Gu. A scholar is included among the top collaborators of Shengying Gu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shengying Gu. Shengying Gu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Shi, Chenyang, et al.. (2024). Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide. Diabetes Obesity and Metabolism. 26(8). 3176–3190. 3 indexed citations
3.
Gu, Shengying, et al.. (2023). Digestive Tract Cancer‐Related Adverse Events Correlated with Proton Pump Inhibitors Use: A Pharmacovigilance Study of the FDA Adverse Event Reporting System. Journal of Clinical Pharmacy and Therapeutics. 2023(1). 2 indexed citations
4.
Gu, Shengying, et al.. (2023). Bidirectional association between NAFLD and gallstone disease: a systematic review and meta-analysis of observational studies. Expert Review of Gastroenterology & Hepatology. 17(3). 283–293. 9 indexed citations
5.
6.
Hu, Shanshan, et al.. (2022). Robust Prediction of Prognosis and Immunotherapy Response for Bladder Cancer through Machine Learning Algorithm. Genes. 13(6). 1073–1073. 5 indexed citations
7.
Hu, Shanshan, et al.. (2022). Cost‐utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China. Diabetes Obesity and Metabolism. 25(2). 387–397. 10 indexed citations
8.
Huo, Yan, et al.. (2020). Identification of the risks in CAR T-cell therapy clinical trials in China: a Delphi study. Therapeutic Advances in Medical Oncology. 12. 3863581614–3863581614. 2 indexed citations
9.
Ma, Zhonghua, Shengying Gu, Min Sup Song, et al.. (2017). Long non-coding RNA SNHG17 is an unfavourable prognostic factor and promotes cell proliferation by epigenetically silencing P57 in colorectal cancer. Molecular BioSystems. 13(11). 2350–2361. 60 indexed citations
10.
Liu, Ying, Xin Wu, Yushuai Mi, et al.. (2017). PLGA nanoparticles for the oral delivery of nuciferine: preparation, physicochemical characterization and in vitro/in vivo studies. Drug Delivery. 24(1). 443–451. 44 indexed citations
11.
Liu, Ying, Xin Wu, Yuan Gao, et al.. (2016). Aptamer-functionalized peptide H<sub>3</sub>CR<sub>5</sub>C as a novel nanovehicle for codelivery of fasudil and miRNA-195 targeting hepatocellular carcinoma. International Journal of Nanomedicine. Volume 11. 3891–3905. 32 indexed citations
12.
Zhang, Dandan, Jigang Zhang, Xin Wu, et al.. (2015). Nuciferine downregulates Per-Arnt-Sim kinase expression during its alleviation of lipogenesis and inflammation on oleic acid-induced hepatic steatosis in HepG2 cells. Frontiers in Pharmacology. 6. 238–238. 61 indexed citations
13.
Zhang, Jigang, Dandan Zhang, Xin Wu, et al.. (2015). Incarvine C suppresses proliferation and vasculogenic mimicry of hepatocellular carcinoma cells via targeting ROCK inhibition. BMC Cancer. 15(1). 814–814. 19 indexed citations
14.
Gu, Shengying, Guanhua Zhu, Yuzhu Wang, et al.. (2014). A sensitive liquid chromatography–tandem mass spectrometry method for pharmacokinetics and tissue distribution of nuciferine in rats. Journal of Chromatography B. 961. 20–28. 34 indexed citations
15.
Zhang, Jigang, Xiaoyu Li, Yuzhu Wang, et al.. (2014). ROCK Is Involved in Vasculogenic Mimicry Formation in Hepatocellular Carcinoma Cell Line. PLoS ONE. 9(9). e107661–e107661. 40 indexed citations
16.
Zhang, Wei, Baoyue Ding, Ren‐Jie Tang, et al.. (2011). Combination of Microneedles with PLGA Nanoparticles as a Potential Strategy for Topical Drug Delivery. Current Nanoscience. 7(4). 545–551. 10 indexed citations
17.
Gu, Shengying, Jing Gao, Xuemei Hou, et al.. (2009). Effects of penetration enhancers on Shuangwu traumatic formula: In vitro percutaneous absorption and in vivo pharmacodynamic evaluation of an herb medicine. European Journal of Pharmaceutics and Biopharmaceutics. 73(3). 385–390. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaohua Pei Breakdown of academic impact, for papers by Wenbin Xu Breakdown of academic impact, for papers by Anhui Gao Breakdown of academic impact, for papers by Die Qian Breakdown of academic impact, for papers by Junli Zhang Breakdown of academic impact, for papers by Puyang Gong Breakdown of academic impact, for papers by Rong Lin Breakdown of academic impact, for papers by Chengwu Shen
Rankless by CCL
2026